← Eichor
Study identifier: NCT06205797 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)

Condition: Glabellar Lines  ·  Sponsor: Huons Biopharma

PhasePhase 3
Planned participants312
Who can joinAll sexes, 19 Years to 65 Years
Healthy volunteersYes

About this study

A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines

This description comes directly from the study's public registry record.

Talk to the study team

Saeroarum Han  ·  82-70-7492-6032  ·  saeroarum@huonsbiopharma.com

Jiwon Kim  ·  82-70-7492-6074  ·  jw.kim@huonsbiopharma.com

Always discuss trial participation with your own doctor first.

Locations (1)

Kangbuk Samsung HospitalSeoul, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06205797